Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: Identification of a novel m6A-related lncRNAs signature and immunotherapeutic drug sensitivity in pancreatic adenocarcinoma

Fig. 3

Prognostic validation of m6A-realted lncRNAs in risk model in the training sets. (A) Difference of survival status and survival time in the high- and the low-risk groups in the training sets. (B) Aggregation of m6A-realted lncRNAs based on distinct risk scores in the training sets. (C) A heat map of 4 prognostic lncRNAs related m6A gene in the training sets. The expression differences of EMSLR (D), AL358944.1 (E), ZNF236-DT (F), AC087501.4 (G) in high- and low-risk groups in the training sets. (H) Kaplan-Meier survival curves demonstrating different OS of patients with PDAC in the high- and the low-risk groups in the training sets

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us